AbbVie

Open: 138.77 Close: 138.93 Change: 0.16

The best way to get information about AbbVie: Use an AI.

This document will help you to evaluate AbbVie without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, year, sale, share, Inc, thirdquarter, company, and the …

Concept Map

Semantic Network

Stock Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenos.

Today's Summary

AbbVie expects full-year earnings in the range of $11.19 to $11.23 per share. CEO Rich Gonzalez says company was aware of potential for an ADC transaction with Daiichi.

Today's News

AbbVie Inc. posted a nearly perfect third-quarter beat Friday, but stock skidded on light aesthetics sales and as Humira sales fell. CEO Rich Gonzalez says company was aware of potential for an ADC transaction with Daiichi that Merck ultimately pounced on, electing to prioritize internal work. AbbVie expects full-year earnings in the range of $11.19 to $11.23 per share. Abbvie shares have fallen 10% since the beginning of the year. AbbVie raises 2023 adj. eps guidance; announces 2024 dividend increase. Company raises adjusted EPS guidance for the full year 2023 from $10.86 - $11.06. Company also announces increase in the companys quarterly cash dividend. AbbVie expects full-year earnings in the range of $11.19 to $11.23 per share. Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, announces a partnership with Abbvie Inc. AbbVie reported third-quarter revenue of $13.9 billion, a 6% decrease year over year. Imbruvica sales were $908 million, a 22% drop from the same period a year ago.

Stock Profile

"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois."

Keywords

The game is changing. There is a new strategy to evaluate AbbVie fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, year, sale, share, Inc, thirdquarter, company, and the most common words in the summary are: abbvie, job, news, best, get, stock, earnings, . One of the sentences in the summary was: AbbVie expects full-year earnings in the range of $11.19 to $11.23 per share. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #abbvie #job #news #best #get #stock #earnings.